Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFMW) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Sunshine Biopharma (SBFMW) over the last 14 years, with Q3 2025 value amounting to $7.3 million.

  • Sunshine Biopharma's Total Liabilities rose 4525.2% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year increase of 4525.2%. This contributed to the annual value of $7.1 million for FY2024, which is 1498.53% up from last year.
  • According to the latest figures from Q3 2025, Sunshine Biopharma's Total Liabilities is $7.3 million, which was up 4525.2% from $6.3 million recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Total Liabilities registered a high of $7.6 million during Q4 2022, and its lowest value of $95234.0 during Q1 2022.
  • Its 5-year average for Total Liabilities is $4.7 million, with a median of $5.7 million in 2023.
  • Per our database at Business Quant, Sunshine Biopharma's Total Liabilities plummeted by 9676.39% in 2022 and then soared by 784030.49% in 2023.
  • Quarter analysis of 5 years shows Sunshine Biopharma's Total Liabilities stood at $2.0 million in 2021, then soared by 282.49% to $7.6 million in 2022, then dropped by 19.39% to $6.1 million in 2023, then grew by 14.99% to $7.1 million in 2024, then rose by 3.24% to $7.3 million in 2025.
  • Its last three reported values are $7.3 million in Q3 2025, $6.3 million for Q2 2025, and $6.5 million during Q1 2025.